Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Munich, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the...
-
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation
-
The Stock Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets
-
Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025. Introducing LLibra OS, a next-generation AI platform that accelerates discovery and...
-
ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 ...
-
BPGbio CEO Dr. Niven R. Narain was named to The Medicine Maker Power List 2025.
-
Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its...
-
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
-
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
-
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...